ORIC Pharmaceuticals Inc. (ORIC)$8.32

Market Cap: 405.19 MCurrency: USD

Research Snapshot

Static fundamentals, valuation context, and investor signals for ORIC Pharmaceuticals Inc. (ORIC).

HEALTHCARE

BIOTECHNOLOGY

DCF ready

Valuation

-3.2x

EV/FCF, N/A FCF yield

Quality

-33.7%

ROIC, N/A FCF margin

Growth

N/A

5Y sales (revenue) CAGR

Balance sheet

0.0x

Debt/equity, 14.1x current ratio

Superinvestors

Top: Meridian Contrarian Fund (0.6%)

Strengths to research

Debt/equity looks manageable at 0.0x.
8 annual periods are available for trend analysis.

Watchouts

No major valuation, balance sheet, or growth watchouts were detected by the static screen.

Annual data: 8 periods

Quarterly data: 24 periods

Stock snapshot: May 25, 2026

Static dataset: May 25, 2026

Quality Scorecard

Build-time composite score for ORIC.

Grade F

/ 100

Peer Comparison

Target stock against 8 market-cap comparable peers.

Heat map: red worst to green best


ORIC Target	ORIC Pharmaceuticals Inc.	$405.2M	-5.7x	-3.2x	-33.7%	N/A	N/A	N/A	N/A	N/A
DNA	Ginkgo Bioworks Holdings Inc.	$402.4M	-1.5x	-1.3x	-0.1%	17.3%	-105.0%	N/A	N/A	N/A
PGEN	Precigen Inc.	$448.7M	-3.1x	-5.7x	-219.7%	-21.3%	-927.6%	N/A	N/A	N/A
TRVI	Trevi Therapeutics Inc.	$667.1M	-44.2x	-15.4x	-23.3%	N/A	N/A	N/A	N/A	N/A
NUVB	Nuvation Bio Inc.	$808.4M	-7.9x	-4.0x	-58.0%	N/A	-275.7%	N/A	N/A	N/A
RCKT	Rocket Pharmaceuticals Inc.	$838.3M	-1.5x	-4.0x	-80.5%	N/A	N/A	N/A	N/A	N/A
INBX	Inhibrx	$178.5M	-11.2x	-0.4x	-1752.2%	N/A	-9986.5%	N/A	N/A	N/A
DMAC	DiaMedica Therapeutics Inc.	$171.4M	N/A	-5.4x	-58.4%	N/A	N/A	N/A	N/A	N/A
PHVS	Pharvaris NV	$1.0B	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Financial Charts

No financial data available for ORIC (annual).

2 superinvestors own ORIC

Current quarter ownership and quarter-over-quarter share changes.

Superinvestor ownership

Fund	Shares	Value	% Portfolio	QoQ Change
Viking Global Investors Viking Global Investors	5,824,533	$74M	0.21%	0.0%
Meridian Contrarian Fund Meridian Contrarian Fund	370,000	$3M	0.57%	0.0%